Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Thames Valley Cancer Network implements ARIA system for Medical Oncology

A chemotherapy software solution that enables patients to become more involved in managing their own care has been successfully rolled out across a network of hospitals in the UK. The Thames Valley Cancer Network has implemented Aria for Medical Oncology™ from Varian Medical Systems and already has more than 850 clinical staff routinely using the system.

12 Jan 2010

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

A $1 million grant from Abraxis Bioscience, Inc. to a world-famous research laboratory at John Wayne Cancer Institute at Saint John’s Health Center could help save lives of cancer patients by helping doctors more rapidly assess whether a treatment is working or not.

12 Jan 2010

Enrollment complete in Dune Medical Devices' MarginProbe pivotal clinical trial

Dune Medical Devices today announced the completion of patient enrollment in the MarginProbe™ pivotal clinical trial. The MarginProbe procedure provides surgeons with real-time detection of cancer at the edges of the tissue removed during breast conservation surgery (BCS), which is the only way to ensure the complete removal of the tumor from the breast. The randomized, controlled trial includes 664 women who underwent BCS at one of 21 leading medical facilities, with 18 in the US and three in Israel.

12 Jan 2010

3D structure of PI3Kdelta: An important drug target for a wide range of diseases

Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.

12 Jan 2010

Older patients with acute myeloid leukemia may benefit from decitabine drug

Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutions.

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Proteus Biomedical signs worldwide license and collaboration agreement with Novartis

Proteus Biomedical Inc., a pioneer in intelligent medicine, entered into an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize pharmaceutical products that incorporate Proteus’ novel sensor-based technologies in the field of organ transplantation.

12 Jan 2010

University Hospitals in Cleveland selects Sectra as PACS provider

University Hospitals in Cleveland, Ohio has selected the IT and medical-technology company Sectra as their PACS provider. University Hospitals has been recognized by Thomson Reuters as a Top 10 hospital system in the U.S., and by U.S. News and World Report as one of America’s best hospitals.

12 Jan 2010

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.

12 Jan 2010

4SC commences treatment in its resminostat Phase II trial for HL

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.

12 Jan 2010

Sage Bionetworks, Pfizer sign new research partnership to analyze advanced network models of cancer

Sage Bionetworks has announced today a new research partnership with Pfizer, Inc. to build, analyze and exploit advanced network models of cancer. Pfizer will provide research funding to Sage to analyze large, globally coherent datasets from Pfizer, Sage and the public domain.

12 Jan 2010

Multigene test results impact physicians and patients' decisions on breast cancer therapy

A 21-gene test that predicts whether early stage breast cancer patients will benefit from chemotherapy is having a big impact on treatment decisions by patients and doctors alike.

12 Jan 2010

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has submitted an investigational new drug (IND) amendment to the United States Food and Drug Administration (FDA) which includes the design of a proposed Phase 3 clinical trial of Neoprobe’s RIGScan® CR radiopharmaceutical.

12 Jan 2010

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

SRI International Dedicates New Tampa Bay Research Facility SRI International, one of the world's leading independent research and technology development organizations, officially opened its new 40,000-square-foot research facility located at the Port of St. Petersburg.

11 Jan 2010

Institut Curie, Ipsogen sign scientific collaboration agreement in breast cancer domain

The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the current scientific knowledge on Ipsogen's MapQuant Dx Grade Genomic, HER2 and HR tests will be increased thanks to new data established from a large population of patients treated at the Institut Curie.

11 Jan 2010

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics announced today that the Company received a $5 million award from the State of Texas through the Texas Emerging Technology Fund (“ETF”). The ETF was created with the goal of growing new and existing businesses to accelerate the introduction of new products and services in the marketplace. This is the largest award of this type that has ever been granted.

11 Jan 2010

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept’s novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

11 Jan 2010

Oncology News and Research

Further Reading

Thames Valley Cancer Network implements ARIA system for Medical Oncology

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

Enrollment complete in Dune Medical Devices' MarginProbe pivotal clinical trial

3D structure of PI3Kdelta: An important drug target for a wide range of diseases

Older patients with acute myeloid leukemia may benefit from decitabine drug

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

VentiRx Pharmaceuticals completes $25 million Series A Extension

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Proteus Biomedical signs worldwide license and collaboration agreement with Novartis

University Hospitals in Cleveland selects Sectra as PACS provider

CEL-SCI completes validation of its GMP manufacturing facility

4SC commences treatment in its resminostat Phase II trial for HL

Sage Bionetworks, Pfizer sign new research partnership to analyze advanced network models of cancer

Multigene test results impact physicians and patients' decisions on breast cancer therapy

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

Institut Curie, Ipsogen sign scientific collaboration agreement in breast cancer domain

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News